Jingjing Ye
Research Subjects
Research Interests
Jingjing Ye has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Lei Nie
Has worked for) the United States Food and Drug Administration
16 shared publications Gregory Reaman
Cytel, Waltham, MA
4 shared publications- Margaret Gamalo
Pfizer Inc. Collegeville Pennsylvania USA
4 shared publications William Wang
4 shared publicationsChengxing (Cindy) Lu
3 shared publications- Haitao Pan
St. Jude Children’s Research Hospital
3 shared publications
Latest Publications
- 30 April 2026
- Published by Taylor & Francis
- p. 99-123
Randomized Screening Selection Design for Pediatric Oncology Trials
The objective of this chapter is to introduce screening selection designs for master protocol pediatric oncology trials with binary and time-to-event endpoints. We will specifically focus on two St. Jude pediatric oncology trials: one in pediatric neuroblastoma and the other in pediatric Ewing sarcoma. The chapter will discuss the methodology and implementation of screening selection designs using the R package frequentistSSDBinary for binary endpoint and frequentistSSD for time-to-event endpoint.
- 30 April 2026
- Published by Taylor & Francis
- p. 99-123
Randomized Screening Selection Design for Pediatric Oncology Trials
The objective of this chapter is to introduce screening selection designs for master protocol pediatric oncology trials with binary and time-to-event endpoints. We will specifically focus on two St. Jude pediatric oncology trials: one in pediatric neuroblastoma and the other in pediatric Ewing sarcoma. The chapter will discuss the methodology and implementation of screening selection designs using the R package frequentistSSDBinary for binary endpoint and frequentistSSD for time-to-event endpoint.
- 30 April 2026
- Published by Taylor & Francis
- p. 381-406
The RECOVERY Trial:
The Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial is a prime example of a platform trial designed to assess the efficacy and safety of various treatments for hospitalized patients with COVID-19 during the pandemic. This chapter introduces the rationale of RECOVERY trial for adopting a platform trial approach and design and operational elements that made the RECOVERY trial successful. Notable pragmatic component is highlighted in the chapter – RECOVERY utilizes the connection to existing real-world data infrastructure (e.g., database collects mortality, hospital admission, and intensive care), thus minimizing the necessary data collection and reducing operational burden. RECOVERY's success in identifying effective therapies has transformed the landscape of COVID-19 clinical trials and inspired new approaches to tackle future medical challenges. The lessons learned from RECOVERY continue to guide the implementation of these approaches in other therapeutic areas and encourage future trials like RECOVERY to be more agile, adaptive, and efficient than traditional clinical trials.
- 30 April 2026
- Published by Taylor & Francis
- p. 381-406
The RECOVERY Trial:
The Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial is a prime example of a platform trial designed to assess the efficacy and safety of various treatments for hospitalized patients with COVID-19 during the pandemic. This chapter introduces the rationale of RECOVERY trial for adopting a platform trial approach and design and operational elements that made the RECOVERY trial successful. Notable pragmatic component is highlighted in the chapter – RECOVERY utilizes the connection to existing real-world data infrastructure (e.g., database collects mortality, hospital admission, and intensive care), thus minimizing the necessary data collection and reducing operational burden. RECOVERY's success in identifying effective therapies has transformed the landscape of COVID-19 clinical trials and inspired new approaches to tackle future medical challenges. The lessons learned from RECOVERY continue to guide the implementation of these approaches in other therapeutic areas and encourage future trials like RECOVERY to be more agile, adaptive, and efficient than traditional clinical trials.
- 30 April 2026
- Published by Taylor & Francis
- p. 322-345
Patient Representation and Accessibility in Master Protocols
Master protocols (MPs) in clinical trials represent an innovative approach where multiple sub-studies are conducted under a single overarching protocol. This design enhances efficiency and flexibility in evaluating treatments across various diseases and patient populations. Two critical pillars to MP success are patient representation and accessibility. MPs should prioritize diverse participant inclusion, considering demographics such as age, gender, race, and ethnicity to ensure results are broadly generalizable. Accessibility entails addressing geographical, physical, financial, and technological barriers that hinder participation. The chapter explores these dimensions to elevate patient voices in trial design and interpretation while ensuring inclusivity through digital health technologies and virtual engagement. Actionable approaches mitigate the barriers that underrepresented communities face and address persistent disparities in research participation. Technological innovations, including electronic patient-reported outcomes, further enhance accessibility. By fostering diverse and inclusive aspects, MPs can bridge gaps in clinical research, creating scientifically robust trials that reflect diverse human experiences. The chapter calls for collaborative efforts to embed varied principles into MPs, envisioning a future where clinical trials are equitable and accessible to all, ensuring better care for patients worldwide.
- 30 April 2026
- Published by Taylor & Francis
- p. 322-345
Patient Representation and Accessibility in Master Protocols
Master protocols (MPs) in clinical trials represent an innovative approach where multiple sub-studies are conducted under a single overarching protocol. This design enhances efficiency and flexibility in evaluating treatments across various diseases and patient populations. Two critical pillars to MP success are patient representation and accessibility. MPs should prioritize diverse participant inclusion, considering demographics such as age, gender, race, and ethnicity to ensure results are broadly generalizable. Accessibility entails addressing geographical, physical, financial, and technological barriers that hinder participation. The chapter explores these dimensions to elevate patient voices in trial design and interpretation while ensuring inclusivity through digital health technologies and virtual engagement. Actionable approaches mitigate the barriers that underrepresented communities face and address persistent disparities in research participation. Technological innovations, including electronic patient-reported outcomes, further enhance accessibility. By fostering diverse and inclusive aspects, MPs can bridge gaps in clinical research, creating scientifically robust trials that reflect diverse human experiences. The chapter calls for collaborative efforts to embed varied principles into MPs, envisioning a future where clinical trials are equitable and accessible to all, ensuring better care for patients worldwide.
- 30 April 2026
- Published by Taylor & Francis
- p. 14-22
Regulatory Landscape
This chapter provides an overview of global regulatory guidance on master protocols. The landscape is based on the guidance from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). Other regions are covered based on publication or guidance sections in the respective countries. Various aspects, including design, data, operational, safety, and biomarkers in the guidance, are illustrated by highlighting similar or different recommendations between the FDA and EMA. The chapter also includes discussion on Health Technology Assessment (HTA)'s view on master protocol and the expectations when assessing trial results.
- 30 April 2026
- Published by Taylor & Francis
- p. 14-22
Regulatory Landscape
This chapter provides an overview of global regulatory guidance on master protocols. The landscape is based on the guidance from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). Other regions are covered based on publication or guidance sections in the respective countries. Various aspects, including design, data, operational, safety, and biomarkers in the guidance, are illustrated by highlighting similar or different recommendations between the FDA and EMA. The chapter also includes discussion on Health Technology Assessment (HTA)'s view on master protocol and the expectations when assessing trial results.
- 30 April 2026
- Published by Taylor & Francis
- p. 3-13
Introduction to Master Protocol Trials
This introductory chapter outlines the scope and objectives of the book, defines key concepts, discusses the strategic advantages of master protocols, and summarizes the evolving regulatory landscape. The chapter highlights key operational and data management considerations unique to master protocol designs, and the need for operational flexibility to accommodate complex and adaptive trial structures. Foundational considerations such as study setup, subject traceability, and documentation at both the master and sub-protocol levels are briefly introduced. The chapter also previews the case studies presented throughout the book, which illustrate practical applications and lessons learned from master protocol execution.
- 30 April 2026
- Published by Taylor & Francis
- p. 3-13
Introduction to Master Protocol Trials
This introductory chapter outlines the scope and objectives of the book, defines key concepts, discusses the strategic advantages of master protocols, and summarizes the evolving regulatory landscape. The chapter highlights key operational and data management considerations unique to master protocol designs, and the need for operational flexibility to accommodate complex and adaptive trial structures. Foundational considerations such as study setup, subject traceability, and documentation at both the master and sub-protocol levels are briefly introduced. The chapter also previews the case studies presented throughout the book, which illustrate practical applications and lessons learned from master protocol execution.
- 30 April 2026
- Published by Taylor & Francis
- p. 305-321
Framework to Include Patient Engagement (PE) in Clinical Trials and Master Protocols (MP)
This framework suggests ways to include PE considerations into all clinical trials, including MPs 1 . These recommendations also help protocols include all patients in the clinical trial process, and includes patient experience research (e.g., Patient-Reported Outcomes (PROs)) 2 . Column A lists each clinical trial component as a distinct step, under general categories (e.g., Study Design Element), which should consider PE factors. Column B lists recommendations to include PE in all types of clinical trials, including MPs. Column C lists recommendations for MPs of all types (i.e., platform, umbrella, basket) in addition to Column B. Examples are not comprehensive. Column D explains specific PE burdens or benefits that may occur in MPs and clinical trials. represent PE considerations for each trial component and are listed by clinical trial subheadings. Notes: Sponsors use different terms to represent multiple sub-studies/protocols that make up a Master Protocol (e.g., DSA/ISA, branch, substudy, subprotocol). For this reason, we use “cohort” as the term in this chart. A cohort describes interventions or population(s) of study participants. Diversity Action Plans 3 : Unique factors that could impact the ability to include all people in clinical trials. PRO is used as the overall term for qualitative research fields that focus on patient-related aspects such as Patient Preference, Patient Experience, Health-Related Quality of Life (HRQOL), and Patient-Reported Outcomes (PRO).
- 30 April 2026
- Published by Taylor & Francis
- p. 305-321
Framework to Include Patient Engagement (PE) in Clinical Trials and Master Protocols (MP)
This framework suggests ways to include PE considerations into all clinical trials, including MPs 1 . These recommendations also help protocols include all patients in the clinical trial process, and includes patient experience research (e.g., Patient-Reported Outcomes (PROs)) 2 . Column A lists each clinical trial component as a distinct step, under general categories (e.g., Study Design Element), which should consider PE factors. Column B lists recommendations to include PE in all types of clinical trials, including MPs. Column C lists recommendations for MPs of all types (i.e., platform, umbrella, basket) in addition to Column B. Examples are not comprehensive. Column D explains specific PE burdens or benefits that may occur in MPs and clinical trials. represent PE considerations for each trial component and are listed by clinical trial subheadings. Notes: Sponsors use different terms to represent multiple sub-studies/protocols that make up a Master Protocol (e.g., DSA/ISA, branch, substudy, subprotocol). For this reason, we use “cohort” as the term in this chart. A cohort describes interventions or population(s) of study participants. Diversity Action Plans 3 : Unique factors that could impact the ability to include all people in clinical trials. PRO is used as the overall term for qualitative research fields that focus on patient-related aspects such as Patient Preference, Patient Experience, Health-Related Quality of Life (HRQOL), and Patient-Reported Outcomes (PRO).
- 30 April 2026
- Published by Taylor & Francis
Master Protocol Clinical Trials for Evidence Generation
Drug development is at a crossroads. As personalized medicine and targeted therapies expand, traditional clinical trial models have become too slow, costly, and
- 30 April 2026
- Published by Taylor & Francis
Master Protocol Clinical Trials for Evidence Generation
Drug development is at a crossroads. As personalized medicine and targeted therapies expand, traditional clinical trial models have become too slow, costly, and
- 30 April 2026
- Published by Taylor & Francis
- p. 62-78
Statistical Considerations for Designing and Analyzing Platform Trials
The objective of this chapter is to provide an overview of the key methodological issues encountered when planning and analyzing the data of a platform trial, such as multiple testing and the use of non-concurrent controls. In addition, some regulatory perspectives will be provided for the case of confirmatory trials.
- 30 April 2026
- Published by Taylor & Francis
- p. 62-78
Statistical Considerations for Designing and Analyzing Platform Trials
The objective of this chapter is to provide an overview of the key methodological issues encountered when planning and analyzing the data of a platform trial, such as multiple testing and the use of non-concurrent controls. In addition, some regulatory perspectives will be provided for the case of confirmatory trials.
- Open Access
A Novel Bayesian Extrapolation Design for Assessing Equivalence in Exposure-Response Curves between Pediatric and Adult Populations
Development of effective treatments in pediatric population poses unique scientific and ethical challenges in addition to the small population. In this regard, both the U.S. and E.U. regulations suggest a complementary strategy, pediatric extrapolation, based on assessing the relevance of existing information in the adult population to the pediatric population. The pediatric extrapolation approach often relies on data extrapolation from adults, contingent upon evidence of similar disease progression, pharmacology and clinical response to treatment between adult and children. Similarity evaluation in pharmacology is usually characterized through the exposure-response relationship. Current methodologies for comparing exposure-response (E-R) curves between these groups are inadequate, typically focusing on isolated data points rather than the entire curve spectrum (Zhang et al., 2021). To overcome this limitation, we introduce an innovative Bayesian approach for a comprehensive evaluation of E-R curve similarities between adult and pediatric populations. This method encompasses the entire curve, employing logistic regression for binary endpoints. We have developed an algorithm to determine sample size and key design parameters, such as the Bayesian posterior probability threshold, and utilize the maximum curve distance as a measure of similarity. Integrating Bayesian and frequentist principles, our approach involves developing a method to simulate datasets under both null and alternative hypotheses, allowing for type I error and type II error control. Simulation studies and sensitivity analyses demonstrate that our method maintains a stable performance with type I error and type II error control.
Open AccessA Novel Bayesian Extrapolation Design for Assessing Equivalence in Exposure-Response Curves between Pediatric and Adult Populations
Development of effective treatments in pediatric population poses unique scientific and ethical challenges in addition to the small population. In this regard, both the U.S. and E.U. regulations suggest a complementary strategy, pediatric extrapolation, based on assessing the relevance of existing information in the adult population to the pediatric population. The pediatric extrapolation approach often relies on data extrapolation from adults, contingent upon evidence of similar disease progression, pharmacology and clinical response to treatment between adult and children. Similarity evaluation in pharmacology is usually characterized through the exposure-response relationship. Current methodologies for comparing exposure-response (E-R) curves between these groups are inadequate, typically focusing on isolated data points rather than the entire curve spectrum (Zhang et al., 2021). To overcome this limitation, we introduce an innovative Bayesian approach for a comprehensive evaluation of E-R curve similarities between adult and pediatric populations. This method encompasses the entire curve, employing logistic regression for binary endpoints. We have developed an algorithm to determine sample size and key design parameters, such as the Bayesian posterior probability threshold, and utilize the maximum curve distance as a measure of similarity. Integrating Bayesian and frequentist principles, our approach involves developing a method to simulate datasets under both null and alternative hypotheses, allowing for type I error and type II error control. Simulation studies and sensitivity analyses demonstrate that our method maintains a stable performance with type I error and type II error control.
- 20 November 2024
- Published by Springer Nature
- p. 459-470
Case Studies